We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hatch-Waxman Amendments, Drug Shortages Lead FDA’s 2025 Legislative Agenda
Hatch-Waxman Amendments, Drug Shortages Lead FDA’s 2025 Legislative Agenda
The FDA’s legislative wish list for FY 2025 includes proposals to protect drug supply resiliency, amend the Hatch-Waxman Act, and exercise greater control over recalls.